Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Instagram Outage Disrupts Thousands of U.S. Users 
HORSHAM, Pa., March 06, 2018 -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced today that its fourth quarter and fiscal 2017 financial results earnings call has been delayed to March 29th. The call has been delayed because additional time is required, due in part to an extended power outage at the Company’s Horsham, PA facility, to complete the company's review of certain accounting matters.
About STRATA Skin Sciences, Inc. (www.strataskinsciences.com)
STRATA Skin Sciences is a medical technology company focused on the therapeutic and aesthetic dermatology market. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; the STRATAPEN® MicroSystem, marketed specifically for the intended use of micropigmentation; and NORDLYS, a multi-technology aesthetic laser device.
| Investor Contacts: | ||
| Frank McCaney, Chief Executive Officer STRATA Skin Sciences, Inc. 215-619-3200 [email protected] | Bob Yedid, Managing Director LifeSci Advisors, LLC 646-597-6989 [email protected] |
